
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+10
BioCentriq is an established, highly collaborative, global cell therapy CDMO. The company has been successfully manufacturing drug products for use in human clinical trials since 2022. In June of 2023, BioCentriq launched its LEAPTM Advanced Therapy Platform which helps cell therapy developers move from contract to clinic in as short as six months. With industry recognized scientists, engineers, analysts, and manufacturing specialists, established quality systems and modern infrastructure, BioCentriq is a proven strategic partner for the development and manufacturing of both autologous and allogeneic cell therapy products. The company was purchased by GC of South Korea for $73M in May...
Cell therapy,clinical manufaturing,process development,tech transfer,cell banking,upstream processing,downstream processing,monoclonal antibodies,gmp production,cell banking,viral banking,allogeneic cell therapies,autologous cell therapies,workforce development,and corporate training
Biocentriq operates in the Pharmaceutical manufacturing industry.
Biocentriq's revenue is 11m - 100m
Biocentriq has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.